Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

As Novavax has its Covid-19 vaccine authorized in multiple major world markets, NVAX stock is overdue for a re-rating on Wall Street. The post Why Novavax Stock Is Due for a Comeback Soon appeared first on InvestorPlace.

Why Novavax Stock Is Due for a Comeback Soon

The uptake of Novavax's COVID-19 vaccine in Germany appears to be disappointing.

Why Novavax Stock Is Slipping Today

BARK

Fastly

Ping Identity Holding Corp

Pinterest

Pubmatic

PayPal

Teladoc

Stock market corrections have always been the ideal time to put money to work.

10 Stocks I've Bought During the Market Sell-Off

American Eagle Outfitters

A small amount of money can go a long way when it's invested in the right stocks.

3 No-Brainer Stocks to Buy With $75 During the Market Sell-Off

Novavax investors are waiting for one big thing.

Is This 1 Element a Red Flag for Novavax?

Covid-19 vaccine maker Novavax's stock has declined by about 18% over the past month, compared to the S&P 500 which remains down by about 3% over the same period. While the broader markets have been weak due to the Russian invasion of Ukraine and expected interest rate hikes by the Federal Reserve.

Down 18% Over The Last Month, What's Next For Novavax Stock?

The company's shares prove resilient to an analyst's price-target cut.

Why Novavax Stock Beat the Market Today

The valuation of NVAX stock is quite attractive while Novavax continues to make progress in many important areas. The post Investors Should Not Lose Faith in Novavax appeared first on InvestorPlace.

Investors Should Not Lose Faith in Novavax

The odds that Novavax wins U.S. Emergency Use Authorization for its vaccine should be pretty good.

Novavax Is Betting Its COVID Vaccine Will Win U.S. Authorization. Should You?

BioNTech SE

Johnson & Johnson

Moderna

Pfizer

Shares of Moderna, BioNTech, Pfizer, Johnson & Johnson and Novavax rose on Monday as China battles its worst Covid outbreak in two years.

Vaccine maker stocks rise as China battles worst Covid outbreak since 2020

Dynavax Technologies

The broader stock market bounce and news from China are fueling gains for all four vaccine stocks.

Why BioNTech, Dynavax, Novavax, and Pfizer Stocks Are Jumping Today

Pfizer Inc. (NYSE: PFE) and Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 4.3% at $52.42 and 9.6% at $80.05 respectively. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

Here's Why Pfizer And Novavax Shares Are Rising On Monday

It could open the door to major gains in the long term.

Is Novavax's Biggest Catalyst Ever Just Ahead?

-  'We Do Vaccines' and 'Know Our Vax' are new educational efforts that provide information regarding vaccines -  Programs explain Novavax' commitment to vaccine development and innovation GAITHERSBURG, Md., March 10, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the launch of its global unbranded 'We Do Vaccines' and 'Know Our Vax' programs, educational efforts aimed to help protect the health of people everywhere in the fight against COVID-19 and other deadly infectious diseases, such as influenza.

Novavax Announces Launch of Global Vaccine Education Programs

It's been more than a month since the company filed for Emergency Use Authorization of its COVID-19 vaccine.

Is FDA Authorization for Novavax's Vaccine Imminent?

Novavax, Inc. (NVAX) Presents at Cowen 42nd Annual Healthcare Conference (Transcript)

Dynavax and Novavax both reported Q4 2021 earnings after hours on 02/28/2022 with heavy pandemic revenues, but only one had earnings. Both issued positive guidance as the state of the pandemic makes future vaccine uptake highly uncertain. Each has non-COVID irons in the fire. The alphavaxers present divergent paths to alpha, take your pick.

The Alphavaxers: Dynavax And Novavax - A Tale Of Two Cities

Investors aren't convinced the biotech has a solid, long-term outlook.

Why Novavax Stock Is Sliding Today

NVAX stock continues to languish for want of evidence for a sustainable fundamental improvement. The 2022 revenue guidance issued by the company did stir some optimism, but investors have quickly fallen back to their guarded stance.

Novavax Revenue Guidance Does Little to Change Neutral Stance on the Stock

Novavax has not provided a definitive timeline for its US EUA approval in its recent earnings call.

Is Novavax Stock A Buy Or Sell As COVID-19 Shot Awaits FDA Approval?

Both companies are predicting billions of dollars in vaccine revenue.

Better Post-Earnings Buy: Moderna or Novavax?

It's all about the coronavirus vaccine of tomorrow.

Here's Why April Could Be a Critical Month for Novavax

Novavax's vaccine story is just getting started.

3 Numbers That Make Novavax a Buy Right Now

GAITHERSBURG, Md., March 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Cowen's 42nd Annual Healthcare Conference.

Novavax to Participate in Cowen's 42nd Annual Health Care Conference

The best chance for profits with NVAX stock is with the international market. But Russia's invasion of Ukraine could put Novavax's strategy at risk.

News for Novavax Stock (NVAX)